Multidrug-resistant Gram-negative bacteria: Difference between revisions

Content deleted Content added

Inline

Latest revision as of 17:08, 27 September 2024

Defined by the European CDC1 as non-susceptibility to at least one agent in three or more categories of antimicrobials, with the categories varying by organism
Refer to to multidrug-resistant organisms for specific

Ceftolozane-tazobactam (Zerbaxa)
- May be better for multidrug-resistance Pseudomonas (or at least more experience with it)
Ceftazidime-avibactam: available through Special Access Program
- Adds coverage of some carbapenemases and AmpC
Fosfomycin
Colistin
Cefiderocol: available through Special Access Program as well as preapproval by manufacturer
Meropenem-vaborbactam: still awaiting Health Canada Drug Review
Imipenem-relebactam (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review

@@ Line 1: / Line 1: @@
 == Background ==
-* Defined by the European CDC<ref>Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. ''Clin Microbiol Infect''. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. PMID: 21793988.</ref> as non-susceptibility to at least one agent in three or more categories of antimicrobials, with the categories varying by organism
+* Defined by the European CDC[[CiteRef::magiorakos2012mu]] as non-susceptibility to at least one agent in three or more categories of antimicrobials, with the categories varying by organism
 * Refer to to [[Multidrug-resistant organism|multidrug-resistant organisms]] for specific